Advances in graft-versus-host disease biology and therapy
暂无分享,去创建一个
[1] J. Bradley,et al. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. , 1997, Journal of immunology.
[2] D. Askew,et al. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. , 2007, The Journal of investigative dermatology.
[3] H. Hashimoto,et al. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. , 1998, Journal of immunology.
[4] A. Gewirtz,et al. Flagellin, a TLR5 Agonist, Reduces Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation Recipients While Enhancing Antiviral Immunity , 2011, The Journal of Immunology.
[5] P. Kristjansen,et al. Interleukin-21 Signaling: Functions in Cancer and Autoimmunity , 2007, Clinical Cancer Research.
[6] J. Ritz,et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] D. Taub,et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. , 1998, The Journal of clinical investigation.
[8] D. Munn,et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. , 2010, Blood.
[9] R. Billingham. The biology of graft-versus-host reactions. , 1966, Harvey lectures.
[10] M. Tanimoto,et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. , 2007, Blood.
[11] M. Robin,et al. Th17/Treg ratio in human graft-versus-host disease. , 2010, Blood.
[12] J. L. F. A. S. Mineishi. Graft Versus Host Disease , 2005 .
[13] S. Setty,et al. IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease , 2008, European journal of immunology.
[14] D. Roopenian,et al. Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation. , 2011, Blood.
[15] W. Murphy,et al. Immunobiology of allogeneic hematopoietic stem cell transplantation. , 2007, Annual review of immunology.
[16] Bruce R. Blazar,et al. Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity , 2011, Science Translational Medicine.
[17] D. Munn,et al. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. , 2009, Blood.
[18] J. Ritz,et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. , 2012, Blood.
[19] Michelle L. West,et al. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. , 2009, Blood.
[20] M. Hessner,et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. , 2009, Blood.
[21] G. Lima,et al. High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. , 2010, Transplantation proceedings.
[22] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[23] W. Pear,et al. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. , 2009, Blood.
[24] R. Storb,et al. The role of B cells in the pathogenesis of graft-versus-host disease. , 2009, Blood.
[25] S. Park,et al. P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. , 2007, Haematologica.
[26] S. Choi,et al. HDAC Inhibition and Graft Versus Host Disease , 2011, Molecular medicine.
[27] E. Yannaki,et al. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. , 2010, Arthritis and rheumatism.
[28] K. Schultz,et al. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. , 1995, Bone marrow transplantation.
[29] M. Martinka,et al. Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. , 2010, Blood.
[30] David Klatzmann,et al. CD4+CD25+ Immunoregulatory T Cells , 2002, The Journal of experimental medicine.
[31] J. Serody,et al. Leukocyte migration and graft-versus-host disease. , 2005, Blood.
[32] C. Fathman,et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.
[33] R. Gress,et al. Th2 and Tc2 Cells in the Regulation of GVHD, GVL, and Graft Rejection: Considerations for the Allogeneic Transplantation Therapy of Leukemia and Lymphoma , 2000, Leukemia & lymphoma.
[34] M. Neurath,et al. IL‐21 regulates experimental colitis by modulating the balance between Treg and Th17 cells , 2007, European journal of immunology.
[35] J. Wagner,et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. , 2011, Blood.
[36] R. Korngold,et al. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. , 2012, Blood.
[37] A. Gabrielli,et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. , 2009, Blood.
[38] E. Gatza,et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. , 2008, Blood.
[39] M. Neurath,et al. IL‐27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1 , 2007, European journal of immunology.
[40] J. Crawford,et al. Tumor Necrosis Factor – a Production to Lipopolysaccharide Stimulation by Donor Cells Predicts the Severity of Experimental Acute Graft-Versus-Host Disease , 1998 .
[41] D. Landau,et al. Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention. , 2011, Blood.
[42] L. Luznik,et al. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation , 2010, Immunologic research.
[43] D. Jain,et al. Graft-versus-Host Disease Is Independent of Innate Signaling Pathways Triggered by Pathogens in Host Hematopoietic Cells , 2011, The Journal of Immunology.
[44] Brit B. Turnbull,et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. , 2009, Blood.
[45] A. D. Panopoulos,et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells , 2007, Nature.
[46] M. V. D. van den Brink,et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. , 2006, Blood.
[47] Jakub Tolar,et al. Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells , 2010, Stem cells.
[48] David Klatzmann,et al. Bone Marrow Mesenchymal Stem Cells Suppress Lymphocyte Proliferation In Vitro but Fail to Prevent Graft-versus-Host Disease in Mice1 , 2006, The Journal of Immunology.
[49] D. Jain,et al. Donor APCs are required for maximal GVHD but not for GVL , 2004, Nature Medicine.
[50] W. Gregory,et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effect , 1988, British journal of haematology.
[51] W. Shannon,et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.
[52] I. Borrello,et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. , 2008, Cancer research.
[53] M. Shlomchik,et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.
[54] Christopher G. King,et al. Absence of P-Selectin in Recipients of Allogeneic Bone Marrow Transplantation Ameliorates Experimental Graft-versus-Host Disease , 2010, The Journal of Immunology.
[55] W. Swaim,et al. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. , 2009, Blood.
[56] A. Panoskaltsis-Mortari,et al. Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1 , 2003, The Journal of Immunology.
[57] K. Indrák,et al. Association of IL6 and CCL2 gene polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation , 2009, Bone Marrow Transplantation.
[58] U. Göbel,et al. Gram-Negative Bacteria Aggravate Murine Small Intestinal Th1-Type Immunopathology following Oral Infection with Toxoplasma gondii1 , 2006, The Journal of Immunology.
[59] J. Goldstein,et al. Regulation of the mevalonate pathway , 1990, Nature.
[60] M. Sykes,et al. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. , 1998, The Journal of clinical investigation.
[61] J. Crawford,et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. , 1998, The Journal of clinical investigation.
[62] S. Lonial,et al. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. , 2001, Blood.
[63] C. Cutler,et al. Rituximab for prevention and treatment of graft-versus-host disease , 2011, International journal of hematology.
[64] O. Abdel-Wahab,et al. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. , 2011, Blood.
[65] T. Yi,et al. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[66] C. Drake,et al. STAT3 Signaling in CD4+ T Cells Is Critical for the Pathogenesis of Chronic Sclerodermatous Graft-Versus-Host Disease in a Murine Model , 2009, The Journal of Immunology.
[67] A. Puisieux,et al. Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus , 2009, Nature Immunology.
[68] D. Munn,et al. IDO in human gut graft-versus-host disease. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[69] J. Ferrara,et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium , 2002, Nature Medicine.
[70] M. Hessner,et al. Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses. , 2009, Blood.
[71] D. Klatzmann,et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. , 2003, The Journal of clinical investigation.
[72] Grazia Gallo,et al. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound , 2007, Journal of leukocyte biology.
[73] S. Ménard,et al. Critical Role of TLR9 in Acute Graft-versus-Host Disease1 , 2008, The Journal of Immunology.
[74] G. Besra,et al. Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration. , 2009, Blood.
[75] J. Tolar,et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). , 2007, Blood.
[76] R. Luong,et al. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. , 2011, Blood.
[77] C. Klein,et al. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. , 2011, Blood.
[78] J. Serody,et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[79] A. Sharpe,et al. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. , 1999, Journal of immunology.
[80] B. Malissen,et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease , 2011, Nature Medicine.
[81] X. P. Liu,et al. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. , 2001, Blood.
[82] D. Allan,et al. Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease. , 2010, Blood.
[83] P. Vyas,et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). , 2012, Blood.
[84] Sudha Kumari,et al. Protein Kinase C-θ Mediates Negative Feedback on Regulatory T Cell Function , 2010, Science.
[85] J. Ritz,et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. , 2009, Blood.
[86] R. Bronson,et al. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. , 2000, The Journal of clinical investigation.
[87] Christopher G. King,et al. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. , 2008, Blood.
[88] E. Holler,et al. Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract. , 2011, Experimental hematology.
[89] F. Uckun,et al. Treatment of Post-Bone Marrow Transplant Acute Graft-Versus-Host Disease with a Rationally Designed JAK3 Inhibitor , 2002, Leukemia & lymphoma.
[90] Y. Ishigatsubo,et al. The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation. , 2012, Leukemia research.
[91] J. Wagner,et al. Generation and Large‐Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft‐Versus‐Host Disease , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[92] U. Grohmann,et al. Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions. , 2011, Current medicinal chemistry.
[93] A. Ganser,et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. , 2009, Blood.
[94] J. Schölmerich,et al. Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. , 2004, Blood.
[95] Christopher G. King,et al. IL-17 contributes to CD4-mediated graft-versus-host disease. , 2009, Blood.
[96] C. Fathman,et al. Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.
[97] Billingham Re. The biology of graft-versus-host reactions. , 1966 .
[98] W. Leonard,et al. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse , 2008, Proceedings of the National Academy of Sciences.
[99] H. Deeg,et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis , 2006, Leukemia.
[100] J. Klein,et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. , 2007, Blood.
[101] M. V. D. van den Brink,et al. CCR2 is required for CD8-induced graft-versus-host disease. , 2005, Blood.
[102] B. Blazar,et al. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.
[103] A. Epstein,et al. Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells , 2010, The Journal of Immunology.
[104] M. V. D. van den Brink,et al. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. , 2010, Blood.
[105] M. Pasquini,et al. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. , 2010, Clinical transplants.
[106] H. Weiner,et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.
[107] J. Serody,et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. , 2005, Blood.
[108] C. Bucher,et al. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. , 2009, Blood.
[109] T. Sayers,et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. , 2005, Blood.
[110] P. Reddy. Pathophysiology of acute graft‐versus‐host disease , 2003, Hematological oncology.
[111] J. Briones,et al. T-Cell Costimulatory Molecules in Acute-Graft-Versus Host Disease: Therapeutic Implications , 2010, Bone marrow research.
[112] W. Janssens,et al. CD4+CD25+ T Cells Lyse Antigen-Presenting B Cells by Fas-Fas Ligand Interaction in an Epitope-Specific Manner 1 , 2003, The Journal of Immunology.
[113] T. Banović,et al. Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. , 2009, Blood.
[114] N. Schmitz,et al. Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study. , 2008 .
[115] J. Allison,et al. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. , 1997, Journal of immunology.
[116] D. Taub,et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. , 1998, The Journal of clinical investigation.
[117] Clare L. Bennett,et al. Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. , 2010, The Journal of clinical investigation.
[118] E. Shevach,et al. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. , 2004, Seminars in immunology.
[119] P. Sehgal,et al. THE RELATIONSHIP OF SERUM IL‐6 LEVELS TO ACUTE GRAFT‐VERSUS‐HOST DISEASE AND HEPATORENAL DISEASE AFTER HUMAN BONE MARROW TRANSPLANTATION , 1992, Transplantation.
[120] M. Pasquini,et al. 2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. , 2013, Clinical transplants.
[121] A. Sepulveda,et al. Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. , 2011, The Journal of clinical investigation.
[122] R. Negrin,et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. , 2010, Blood.
[123] B. Blazar,et al. Acute graft-versus-host disease: from the bench to the bedside. , 2005, Blood.
[124] S. Lonial,et al. Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation , 2001 .
[125] C. Anasetti,et al. Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[126] F. P. Nestel,et al. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease , 1992, The Journal of experimental medicine.
[127] B. Finlay,et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. , 2007, Cell host & microbe.
[128] M. Idzko,et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R , 2010, Nature Medicine.
[129] J. Vossen,et al. IFN-γ-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells , 1998, Bone Marrow Transplantation.
[130] M. V. D. van den Brink,et al. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. , 2011, Blood.
[131] Angela Panoskaltsis-Mortari,et al. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. , 2008, Blood.
[132] S. Varambally,et al. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. , 2012, Blood.
[133] Charles P. Lin,et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues , 2006, The Journal of experimental medicine.
[134] M. Tanimoto,et al. FTY720 enhances the activation‐induced apoptosis of donor T cells and modulates graft‐versus‐host disease , 2007, European journal of immunology.
[135] R. Storb,et al. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[136] R. Noelle,et al. Cd4+Cd25+ Immune Regulatory Cells Are Required for Induction of Tolerance to Alloantigen via Costimulatory Blockade , 2001, The Journal of experimental medicine.
[137] H. Sano,et al. The Protective Role of Host Toll-Like Receptor-4 in Acute Graft-Versus-Host Disease , 2010, Transplantation.
[138] M. Prlic,et al. PKCθ Is Required For Alloreactivity And GVHD But Not For Immune Responses Toward Leukemia And Infection In Mice , 2010 .
[139] D. Jain,et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. , 2008, Blood.
[140] R. Steinman,et al. Dendritic cells induce antigen-specific regulatory T cells that prevent graft versus host disease and persist in mice , 2011, The Journal of experimental medicine.
[141] J. Pidala,et al. Ustekinumab demonstrates activity in glucocorticoid-refractory acute GVHD , 2012, Bone Marrow Transplantation.
[142] Michael Loran Dustin,et al. PKC-θ function at the immunological synapse: prospects for therapeutic targeting. , 2011, Trends in immunology.
[143] C. Dinarello,et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[144] C. Divino,et al. Development and Function of Myeloid‐Derived Suppressor Cells Generated From Mouse Embryonic and Hematopoietic Stem Cells , 2010, Stem cells.
[145] J. Buckner. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases , 2010, Nature Reviews Immunology.
[146] Pei Su,et al. EMBRYONIC STEM CELLS/INDUCED PLURIPOTENT STEM CELLS High-Efficiency Induction of Neural Conversion in Human ESCs and Human Induced Pluripotent Stem Cells with a Single Chemical Inhibitor of Transforming Growth Factor Beta Superfamily Receptors , 2010 .
[147] D. Boumpas,et al. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients , 2004, Lupus.
[148] R. Bronson,et al. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. , 2003, The Journal of clinical investigation.
[149] G. Hill,et al. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. , 2000, Blood.
[150] U. Duffner,et al. Host Dendritic Cells Alone Are Sufficient to Initiate Acute Graft-versus-Host Disease1 , 2004, The Journal of Immunology.
[151] M. Pittenger,et al. Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.
[152] Jingwu Z. Zhang,et al. A New Approach to the Blocking of Alloreactive T Cell-Mediated Graft-versus-Host Disease by In Vivo Administration of Anti-CXCR3 Neutralizing Antibody1 , 2008, The Journal of Immunology.
[153] J. Loutit,et al. “SECONDARY DISEASE” OF RADIATION CHIMERAS: A SYNDROME DUE TO LYMPHOID APLASIA , 1962, Annals of the New York Academy of Sciences.
[154] S. Dillon,et al. Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. , 2012, Blood.
[155] T. Yi,et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. , 2008, Blood.
[156] R. Storb,et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.
[157] Katsuaki Sato,et al. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. , 2003, Immunity.
[158] E. Waller,et al. Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[159] G. Szot,et al. Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-vs.-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients. , 1999, Biology of Blood and Marrow Transplantation.
[160] P. Kebriaei,et al. Treatment of graft-versus-host-disease with mesenchymal stromal cells. , 2011, Cytotherapy.
[161] J. Gribben,et al. Transplantation of anergic histoincompatible bone marrow allografts. , 1999, The New England journal of medicine.
[162] T. Macdonald,et al. IL-21 Counteracts the Regulatory T Cell-Mediated Suppression of Human CD4+ T Lymphocytes1 , 2007, The Journal of Immunology.
[163] E. Waller,et al. Dichotomous Role of Interferon-? in Allogeneic BoneMarrow Transplant , 2009 .
[164] A. McKenzie,et al. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. , 2008, Experimental hematology.
[165] V. Bronte,et al. Myeloid-derived suppressor cell heterogeneity and subset definition. , 2010, Current opinion in immunology.
[166] J. Lohr,et al. Cutting Edge: The Link between Lymphocyte Deficiency and Autoimmunity: Roles of Endogenous T and B Lymphocytes in Tolerance1 , 2005, The Journal of Immunology.
[167] I. Kerr,et al. Jaks and Stats in signaling by the cytokine receptor superfamily. , 1995, Trends in genetics : TIG.
[168] Adrian P Gee,et al. Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.
[169] T. Utsugi,et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. , 2003, Immunity.
[170] D. Jain,et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. , 2004, Blood.
[171] M. Pasquini,et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. , 2009, Blood.
[172] R. Negrin,et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. , 2011, Blood.
[173] R. J. Hocking,et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.
[174] E. Thiel,et al. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease , 2010, Gut.